title: Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
abstract: In a retrospective analysis of 24 children with refractory or multiply relapsed acute lymphoblastic leukemia (ALL), a salvage regimen comprising amsacrine, etoposide, and high-dose methylprednisolone AEP achieved a significant treatment response in 11 of 19 evaluable patients (8 complete and 3 partial remissions). Five of 9 AEP-responsive patients who underwent subsequent stem cell transplantation are alive (median follow-up: 43 months; range 10 to 91). The load of minimal residual disease prior to transplantation appears to be predictive for outcome in this very poor-prognosis subgroup of ALL.
authors.forename: Martin A
authors.initials: MA
authors.lastname: Horstmann
authors.forename: Wolf-Achim
authors.initials: WA
authors.lastname: Hassenpflug
authors.forename: Udo
authors.initials: U
authors.lastname: zur Stadt
authors.forename: Gabi
authors.initials: G
authors.lastname: Escherich
authors.forename: Gritta
authors.initials: G
authors.lastname: Janka
authors.forename: Hartmut
authors.initials: H
authors.lastname: Kabisch
mesh_terms: D000293:Adolescent; D000677:Amsacrine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003907:Dexamethasone / Q000008:administration & dosage; D004341:Drug Evaluation; D004357:Drug Synergism; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007223:Infant; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy / Q000601:surgery; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D018365:Neoplasm, Residual; D036102:Peripheral Blood Stem Cell Transplantation; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000601:surgery; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D011994:Recombinant Proteins; D012074:Remission Induction; D012189:Retrospective Studies; D016879:Salvage Therapy; D016019:Survival Analysis; D013852:Thiotepa / Q000008:administration & dosage; D019772:Topotecan / Q000008:administration & dosage; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D011994:Recombinant Proteins; D000677:Amsacrine; D003561:Cytarabine; D003841:Deoxycytidine; D016179:Granulocyte Colony-Stimulating Factor; D014747:Vinblastine; D005047:Etoposide; D019772:Topotecan; D003907:Dexamethasone; D013852:Thiotepa; D014740:Vidarabine; D000069585:Filgrastim; D008775:Methylprednisolone; D015255:Idarubicin